Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.48Last Year’s EPS
-0.72Same Quarter Last Year
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -6.67%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Relmada's successful strategic acquisitions and pipeline developments with NDV-01 and Sepranolone, indicating a positive direction for future growth. However, challenges such as the discontinuation of REL-1017, significant cash burn, and reevaluation of REL-P11 development present ongoing hurdles.Company Guidance
During the fourth quarter 2024 financial results call for Relmada Therapeutics, the company outlined several key metrics and strategic priorities. Relmada reported cash, cash equivalents, and short-term investments of approximately $44.9 million as of December 31, 2024, a decrease from $96.3 million the previous year. Cash used in operations for Q4 2024 was $8.8 million, down from $10.2 million in Q4 2023. The company emphasized its focus on progressing its product pipeline with NDV-01 and Sepranolone, following the discontinuation of Phase 3 studies of REL-1017. Research and development expenses decreased to $11 million from $14.7 million in the same period last year, primarily due to completed clinical trials for REL-1017. General and administrative expenses were also reduced to $8.1 million from $12.1 million, largely due to decreased stock-based compensation. The net loss for Q4 2024 was $18.6 million compared to $25.1 million the previous year. Looking forward, Relmada plans to present initial proof-of-concept data for NDV-01 at the American Urological Association Meeting in April 2025, and is preparing for regulatory discussions with the FDA to advance their clinical programs.Strategic Product Acquisition Success
Relmada successfully acquired two new product candidates, NDV-01 and Sepranolone, aligning with their strategic goal to maximize shareholder value through innovation and targeting underserved markets.
NDV-01 Promising Pipeline Development
NDV-01 is currently in Phase 2 for high-grade non-muscle invasive bladder cancer, with top-line data expected at the American Urological Association Meeting in April 2025. It shows potential for innovation and near-term value creation.
Sepranolone Acquisition for Compulsion Disorders
Sepranolone, acquired for Tourette syndrome and other compulsive disorders, is a Phase 2b ready program with promising Phase 2a results and robust safety data from over 350 subjects.
Decreased Operating Expenses
Research and development expenses decreased by $3.7 million and general administrative expenses decreased by $4 million in Q4 2024 compared to Q4 2023, indicating efficient resource management.
---
RLMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RLMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $0.30 | $0.30 | 0.00% |
| Nov 07, 2024 | $3.26 | $3.28 | +0.61% |
| Aug 07, 2024 | $3.24 | $2.30 | -29.01% |
| May 08, 2024 | $3.83 | $3.80 | -0.78% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Relmada Therapeutics (RLMD) report earnings?
Relmada Therapeutics (RLMD) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Relmada Therapeutics (RLMD) earnings time?
Relmada Therapeutics (RLMD) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RLMD EPS forecast?
RLMD EPS forecast for the fiscal quarter 2025 (Q1) is -0.48.
---